Please Read Our Disclaimer
King-Devick technologies, inc.
Location: Oakbrook Terrace, Illinois
Sector: Technology, Software, Health, Life Sciences
King-Devick technologies, inc. (KDT) offers a broad set of evidence-based SaaS model tools utilizing integrated technology for concussion management, balance evaluation, reading solutions and as indicators of neurological function for chronic neuro-degenerative diseases such as Alzheimer’s disease, Parkinson’s disease, MS, migraine headaches, sleep deprivation, hypoxia and macular degeneration.
King-Devick products have been scientifically validated in more than 150 recent peer-reviewed articles published in elite medical journals. In 2015, Mayo Clinic and King-Devick Test announced a co-branding licensing agreement for the sideline concussion test – now recognized as the King-Devick Test in association with Mayo Clinic.
For more information, please visit: www.kingdevick.com.
1. Co-Branded with the number one health care provider/hospital in the United States, Mayo Clinic
The King-Devick Test in association with Mayo Clinic is utilized on rinksides, sidelines and pitchsides all over the world including all players and teams in the National Hockey League and Canadian Football League and many other teams, leagues and schools.
2. More than 150 peer-reviewed articles published in elite neurology journals have validated our products over the last 6 years
Using an evidence-based approach has resulted in unsurpassed credibility related to our product releases. Every product we have has been validated by independent research before we go to market with it.
3. We have three business verticals with a total addressable 12 Billion USD Total Addressable Market annually in a SaaS Model of sales
Our business verticals are:
- Concussion Management – sideline screening and clinical management of recovery
- Neurological Function – chronic management of neurodegenerative conditions
- Reading Performance – teaching the physical act of reading in schools to improve reading outcomes.
4. Experienced management with a long history of prior IPO success
CEO Steve Devick has been successful in founding/co-founding several startups to Nasdaq IPOs including a software company (NASDAQ: PLAT) which sold for $3.6 Billion after its IPO.
Doug Laux, CFO has been the CFO of 3 separate companies with over $1B in revenue each including Alamo/National Rental car and has extensive public company management experience.
5. Extensive media coverage
KDt has been extensively covered in the national and international press.
6. Innovative technology and strong IP
KDt products provide users simplicity and ease of use with clear and objective results for users ranging from parents and coaches to health care providers.
KDt web and mobile applications platforms utilize safe and secure cloud-based technology optimized for telemedicine and includes more than 70 IP registrations in effect including copyright, patents, patents pending, and trademarks registered.
1. Known brand with Mayo Clinic
Mayo Clinic co-branding helps with market recognition all over the world.
2. Peer-reviewed established and validated scientific products
Scientifically vetted and validated products which are already in the market
3. Experienced management
The CEO, CFO and Board of Directors are extremely experienced in all aspects of successfully completing an Initial Public Offering.
Steve Devick, Chief Executive Officer, President, Chairman
Steve Devick, Chairman and CEO of King-Devick technologies, inc. has been a career entrepreneur. Throughout his tenure in the business world, he has founded multiple successful companies, including the King-Devick technologies, inc., a company that allowed him for the first time to combine his healthcare background with his business acumen.
In 2015, Mayo Clinic, for the first time in its 150-year history, executed a co-branding equity contract with an outside company, King-Devick technologies, inc. The sideline screening product is now called the King-Devick Test in association with Mayo Clinic (KDT).
In 2017, Dr. Devick, along with Dr. David Dodick, Professor of Neurology at Mayo Clinic, testified before the Senate Armed Service Committee Meeting with an update on research, diagnosis and treatment for traumatic brain injury and concussion in United States Servicemembers. In May, KDt was selected as a winner of the 2017 VA InnoVAtion Awards for its Recovery Acceleration Program; furthering the opportunity to provide rehabilitative technology for Veterans impacted by TBI.
In addition to King-Devick technologies, inc., Devick has founded/co-founded a series of successful public and private companies. In 1987, Platinum technology (NASDAQ: PLAT) was co-founded and in 1999 was sold for $3.6 billion-more than any software company had sold for prior to that date. Devick was also a founding director in Blue Rhino (NASDAQ: RINO), a propane cylinder exchange company in 2004 was sold for over $400M; Devick also founded Platinum Entertainment, which was the world’s largest independent, publicly traded (NASDAQ: PTET) music company.
In addition to founding and co-founding multiple businesses, Devick also produced a feature length film, Head Games: The Global Concussion Crisis, which addressed the epidemic of concussions in sports, and was directed by Academy Award honored Steve James. Head Games won Best Documentary at the Boston Film Festival and many other awards including Best Sports Documentary from both Sports Illustrated and iTunes.
Devick was recognized by Crain’s Chicago Business as one of the Forty Under Forty business leaders; a regional finalist in Ernst & Young’s Entrepreneur of the Year; New City’s Most Influential People Top 20; and Chairman of the Young Presidents Organization (YPO). He also received the Ernst Jokl Sports Medicine Award from the United States Sports Academy for outstanding sports related medical research. In 2015, the King-Devick Test in association with Mayo Clinic was awarded the Chicago Innovation Award. KDT was selected as a winner from 535 semi-finalists, and 100 finalists. In 2016 Devick received the Innovation of the Year Award from the Concussion Legacy Foundation. In 2018, the company was listed as a Top 10 Health Care Innovation by the Mayo Clinic.
Doug Laux, Chief Financial Officer/Chief Operating Officer, Director
Doug Laux spent the first 20 years of his career with Ernst and Young, the last 9 as a partner in the Chicago office. Doug has extensive experience with both public and private companies as CFO including ANC Rental Corporation the former $2.5 billion parent of Alamo and National Car Rental Companies, EaglePicher, a $900 million diversified manufacturing company, and Remy International, a $1.3 billion automotive supplier.
He was also CFO/COO of Platinum Entertainment Inc., a NASDAQ listed music company he helped take public in 1996. Doug was also a former director and chairman of the audit committee of Sirva, Inc., the parent of Allied and NorthAmerican Van Lines, prior to its sale and R. J. O’Brien and Associates, the oldest and largest independent futures brokerage and clearing firm in the US.
He is also a director of Freeport Securities Company, a family owned oil and gas company. Doug is a graduate of the University of Illinois, with a BS in Accountancy who successfully passed the CPA examination in 1975.
Casey Cowell, Director
Mr. Casey Cowell serves as Chairman and Principal Owner of Durandal, Inc. Mr. Cowell co-founded U.S. Robotics, Inc. in 1976 and served as its Chairman and CEO from 1979 until 1996 when it was merged into 3Com Corp.
Mr. Cowell has served as a Director of 3Com Corp., CDW Corp., and many private companies. Mr. Cowell is a 1975 graduate of the University of Chicago.
Jon Cronin, Director
The Cronin Group, LLC is a Boston-based company with its headquarters at Liberty Wharf in Boston’s thriving Seaport District. Led by Principal Jon Cronin, and with over 2000 employees, the group has been developing residential and commercial real estate for over 20 years and is one of the most prominent restaurant developers in Boston.
Community involvement and charitable endeavors have been, and continue to be, a core value of The Cronin Group. Mr. Cronin sits on the board of the South Boston Neighborhood House and the South Boston Collaborative Center, as well as being involved with his wife Nicole in many other local charities.
David Dodick, MD, Professor of Neurology – Concussions/Sports Medicine, Mayo Clinic
Mr. Dodick serves as Chairman and Member of Medical Advisory Board of Neuralieve Inc. He serves as a Member of Advisory Board at Alder Biopharmaceuticals Inc. Dr. Dodick is co-director of the Annual Scientific Meeting of the American Headache Society and a member of the Scientific Committee of the Migraine Trust.
He is a member of the Board of Governors, executive committee, and serves as secretary of the American Headache Society (AHS). He is also the secretary of the Headache & Facial Pain Section of the American Academy of Neurology (AAN), and chairman of Headache and Facial Pain for the Annual AAN meeting. He is associate editor of Cephalalgia and Headache, editor-in-chief of Headache Currents, and on the editorial board for The Neurologist and Postgraduate Medicine.
He is the program director of the Mayo Clinic Neurology Residency Program in Scottsdale, Arizona, and co-chair of the AHS Evidence-Based Neurology Training Program in the United States. Dr. Dodick is board certified by both the Royal College of Physicians and Surgeons of Canada, and the American Board of Psychiatry and Neurology.
He received his medical degree with distinction from Dalhousie University in Halifax, Nova Scotia, Canada. He completed his internship and neurology residency at the Mayo Clinic in Rochester, Minnesota, followed by fellowships in Headache and Cerebrovascular Diseases at the University of Toronto, in Ontario Canada.
Barbara J. Keller – Director, Technology Licensing Manager II, Mayo Clinic Ventures
Mayo Clinic Ventures is dedicated to converting Mayo’s ideas, ingenuity, and expertise into health care products and services. Before joining Mayo Clinic Ventures, Barb worked as a Contract Manager with Mayo Clinic’s Legal Contract Administration and as an IP Analyst for IBM.
Ms. Keller received her B.S. from Winona State University and her M.A. degree in both Health and Human Service Administration and Management from Saint Mary’s University.
Chad Smith – Director, Founder, Liberty Advisor Group
Chad has 29 years of consulting experience with an emphasis on technology strategy, M&A integration, operations improvement, and pricing optimization. His deep knowledge of technical systems provides clients with solutions for their business and emerging technology concerns that positively impact their top line growth and bottom line profitability.
Prior to founding Liberty, Chad worked with Accenture, James Martin, and Co., and led the Consumer-Packaged Goods, Travel and Entertainment Manufacturing & Distribution, Telecommunications, and Government practices at Diamond Management and Technology Consultants. Chad holds a B. A. in Business Administration from Notre Dame University.
Robert A. Stern – Director, Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine where he is also Director of the Clinical Core of the BU Alzheimer’s Disease and CTE Center
Dr. Stern oversees clinical research studies related to Alzheimer’s disease, including clinical trials for the diagnosis, treatment, and prevention of AD. In addition, his research involves the long-term effects of repetitive head impacts in athletes, including the neurodegenerative disease, CTE.
Dr. Stern has received several NIH and other national grants, has over 250 publications, and is a Fellow of both the American Neuropsychiatric Association and the National Academy of Neuropsychology. His is also the Chair of the Advisory Council to the Medical Scientific Committee of the Massachusetts and New Hampshire Chapter of the Alzheimer’s Association.
He is on the Medical Advisory Board of the Concussion Legacy Foundation and is also a member of the Mackey-White Traumatic Brain Injury Committee of the NFL Players Association.